JAN 29, 2021 5:20 AM PST

Shorter radiation course effective for men with high-risk prostate cancer

Could shortening radiation courses for men undergoing treatment for prostate cancer be just as effective as conventional, longer courses? New research from the UCLA Jonsson Comprehensive Cancer Center suggests this just may be the case. Their findings are published in The International Journal of Radiation Oncology.

Men with high-risk prostate cancer typically undergo radiation courses that last 45 days. Such traditional courses require daily visits for treatment and can be burdensome for many men and their families, drastically altering the quality of life. Now new findings suggest that shortening radiation therapy from six-and-a-half weeks to five days of large-dose delivery may be a safe and effective alternative.

The shorter regimen consists of what is called stereotactic body radiotherapy (SBRT), which is a form of external beam radiation therapy that uses a higher dose of radiation than the 45-day course of radiotherapy. SBRT has been previously shown to be effective for men with low- and intermediate-risk prostate cancer, boasting a four-year cure rate of 82%.

In the study conducted, the researchers considered the efficacy and toxicity of SBRT in high-risk prostate cancer in seven institutional phase II trials and prospective registries. In their analysis, the team looked at data from 344 men with high-risk prostate cancer. The minimum follow-up was 24 months and the median follow-up was 49.5 months. They found that severe side effects from SBRT were rare, with approximately 2% of men experiencing urinary issues and less than 1% experiencing bowel side effects.
 

These data provide evidence that SBRT offers a safe and effective alternative treatment for men with high-risk prostate cancer. While the team cautions that more prospective studies are needed to evaluate the optimal dose and target volume, they say their findings represent a significant advancement that could improve the overall quality of life for patients.

Sources: The International Journal of Radiation Oncology, Eureka Alert

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
FEB 19, 2021
Cancer
Deep learning helps predict lung cancer
FEB 19, 2021
Deep learning helps predict lung cancer
A study from Penn State Great Valley researchers describes how a deep learning model could be used to predict the surviv ...
MAR 15, 2021
Cell & Molecular Biology
Newly-ID'ed Organelle May Play a Role in Cancer Metastasis
MAR 15, 2021
Newly-ID'ed Organelle May Play a Role in Cancer Metastasis
Cells are packed full of organelles and molecules like proteins floating in a liquid known as cytoplasm. In recent years ...
MAR 22, 2021
Immunology
Gene Mutation Keeps Tumors "Cold"
MAR 22, 2021
Gene Mutation Keeps Tumors "Cold"
Immunologists have identified a mechanism through which an oncogene mutation shields pancreatic tumors from immune cells ...
MAR 22, 2021
Cell & Molecular Biology
Improving Cancer Immunotherapy While Reducing Autoimmune Side Effects
MAR 22, 2021
Improving Cancer Immunotherapy While Reducing Autoimmune Side Effects
Immunotherapy aims to make a patient's immune cells better at fighting cancer. The immune system has to be used carefull ...
APR 01, 2021
Immunology
Tumor-Killing 101: Vaccine Trains Immune Cells to Keep Skin Cancer at Bay
APR 01, 2021
Tumor-Killing 101: Vaccine Trains Immune Cells to Keep Skin Cancer at Bay
Cancer researchers have developed a therapeutic vaccine for melanoma, a deadly form of skin cancer. Instead of protectin ...
APR 04, 2021
Drug Discovery & Development
Ion-Pump for Chemotherapy
APR 04, 2021
Ion-Pump for Chemotherapy
Patients of malignant brain tumors experience recurrences even after subsequent treatments. To address this issue, scien ...
Loading Comments...